Table 1: Performance of AITL and the baselines in terms of prediction AUROCMethod/Drug	Bortezomib	Cisplatin	Docetaxel	Paclitaxel(Geeleher et al., 2014)	^^048	0.58	0.55	0.53MOLI (Sharifi-Noghabi et al., 2019b)	0.57	0.54	0.54	0.53(Chen et al., 2017)	0.54±0.07	0.60±0.14	0.52±0.02	0.58±0.04ADDA (Tzeng et al., 2017)	0.51±0.06	0.56±0.06	0.48±0.06	did not convergeProtoNet (Snell et al., 2017)	0.49±0.01	0.40±0.003	0.40±0.01	did not convergeAITL-AD	0.69±0.03^^	0.57±0.03	0.57±0.05	0.58±0.01AITL-DG	0.69±0.04	0.62±0.1	0.48±0.03	0.62±0.02AITL-DC	0.69±0.03	0.54±0.1	0.59±0.07	0.59±0.03AITL	0.74±0.02^^	0.66±0.02	0.64±0.04	0.61±0.04global discriminator, which means the network only employs the multi-task subnetwork and class-wise discriminators. AITL-DC denotes a version of AITL without the class-wise discriminators,which means the network only contains the multi-task subnetwork and the global discriminator.
Table A1: Definition of biological terminologiesTerm	DefinitionCell lines	Human cells that have been immortalized to grow continu- ously in the laboratory.
Table A2: Characteristics of the datasetsDataset	Resource	Drug	Usage	Sample SizeGSE55145 (Amin et al., 2014)	clinical trial	Bortezomib	target	67GSE9782-GPL96 (Mulligan et al., 2007)	clinical trial	Bortezomib	target	169GDSC (Iorio et al., 2016)	cell line	Bortezomib	source	391GSE18864 (Silver et al., 2016)	clinical trial	Cisplatin	target	24GSE23554 (Marchion et al., 2011)	clinical trial	Cisplatin	target	28TCGA (Ding et al., 2016)	patient	Cisplatin	target	66GDSC (Iorio et al., 2016)	cell line	Cisplatin	source	829GSE25065 (Hatzis et al., 2011)	clinical trial	Docetaxel	target	49GSE28796 (Lehmann et al., 2011)	clinical trial	Docetaxel	target	12GSE6434 (Chang et al., 2005)	clinical trial	Docetaxel	target	24TCGA (Ding et al., 2016)	patient	Docetaxel	target	16GDSC (Iorio et al., 2016)	cell line	Docetaxel	source	829GSE15622 (Ahmed et al., 2007)	clinical trial	Paclitaxel	target	20GSE22513 (Bauer et al., 2010)	clinical trial	Paclitaxel	target	14GSE25065 (Hatzis et al., 2011)	clinical trial	Paclitaxel	target	84PDX (Gao et al., 2015)	animal (mouse)	Paclitaxel	target	43TCGA (Ding et al., 2016)	patient	Paclitaxel	target	35GDSC (Iorio et al., 2016)	cell line	Paclitaxel	source	389
Table A3: Performance of AITL and its variants in terms of prediction AUPRMethod/Drug	Bortezomib	Cisplatin	Docetaxel	PaclitaxelAITL-AD	0.72±0.04	0.85±0.06	0.74±0.02	0.63±0.02AITL-DG	0.70±0.07	0.83±0.06	0.76±0.009	0.65±0.03AITL-DC	0.70±0.05	0.81±0.08	0.74±0.04	0.63±0.02AITL	0.76±0.02	0.89±0.03	0.78±0.007	0.63±0.0414Under review as a conference paper at ICLR 2020A.2 Selected hyper-parametersSelected hyper-parameters for MOLI (Sharifi-Noghabi et al., 2019b):Drug	Selected hyper-parametersBortezomib	64 (number of nodes in the hidden layer), 1.5 (margin for the triplet loss), 0.0001 (encoder subnetwork learning rate), 40 (epochs), 0.7 and 0.3 (encoder and classi- fier dropout rates), 0.01 (weight decay), 0.5 (classifier learning rate), 0.2 (regular- ization coefficient), 36 (batch size).
